{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:35Z","timestamp":1790388995549,"version":"4.1.0"},"reference-count":13,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>Community-associated methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (CA-MRSA) is one of the most common pathogens causing pediatric infections including skin and soft tissue infections, pyogenic arthritis, osteomyelitis, and septic shock. For decades, patients were treated with antibiotics such as vancomycin and clindamycin, but there is an increasing incidence of resistance to these traditional therapies. We describe 2 cases of patients with CA-MRSA invasive infections with bacteremia who experienced vancomycin therapy failure but who were successfully treated with ceftaroline fosamil. Case 1 involves an 8-year-old Hispanic male who was diagnosed with CA-MRSA bacteremia, thigh abscess, and osteomyelitis. The patient was admitted to the pediatric intensive care unit in septic shock. Case 2 involves an 8-year-old Caucasian male who was diagnosed with CA-MRSA sepsis, right arm abscess, and osteomyelitis. We were able to successfully treat both patients with CA-MRSA sepsis and invasive infection\u2014who failed vancomycin therapy\u2014with ceftaroline fosamil with no adverse efiects. Despite the positive outcome in both pediatric patients, clinical trials with ceftaroline fosamil are needed to further support its use in pediatric patients.<\/jats:p>","DOI":"10.5863\/1551-6776-20.6.476","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T19:13:17Z","timestamp":1452193997000},"page":"476-480","source":"Crossref","is-referenced-by-count":3,"title":["Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections"],"prefix":"10.5863","volume":"20","author":[{"given":"Amanda W.","family":"Williams","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huntsville Hospital for Women and Children, Huntsville, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huntsville Hospital for Women and Children, Huntsville, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ocheltree","sequence":"additional","affiliation":[{"name":"Huntsville Hospital, Huntsville, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Beaty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huntsville Hospital for Women and Children, Huntsville, Alabama"},{"name":"Department of Pharmacy, Texas Children's Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Huntsville Hospital, Huntsville, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"1","key":"i1551-6776-20-6-476-b1","series-title":"Clin Infect Dis","first-page":"1","article-title":"Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America","volume":"48","year":"2009","unstructured":"Boucher\n              HW, \n            \n              Talbot\n              GH, \n            \n              Bradley\n              JS, \n          \n          et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1\u201312."},{"issue":"4","key":"i1551-6776-20-6-476-b2","series-title":"Pediatrics","first-page":"e817","article-title":"Trends in invasive methicillin-resistant Staphylococcus aureus infections","volume":"132","year":"2013","unstructured":"Iwamoto\n              M, \n            \n              Mu\n              Y, \n            \n              Lynfield\n              R, \n          \n          et al. Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics. 2013;132(4):e817\u2013e824."},{"issue":"suppl 3","key":"i1551-6776-20-6-476-b3","series-title":"Clin Infect Dis","first-page":"S173","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","year":"2012","unstructured":"File\n              TM\n              Jr\n            , WilcoxMH, SteinGE.\n          Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(suppl 3):S173\u2013S180."},{"issue":"suppl 4","key":"i1551-6776-20-6-476-b4","series-title":"J Antimicrob Chemother","first-page":"iv41","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","year":"2010","unstructured":"Corey\n              GR, \n            \n              Wilcox\n              MH, \n            \n              Talbot\n              GH, \n          \n          et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv41\u2013iv51."},{"key":"i1551-6776-20-6-476-b5","series-title":"Teflaro [package insert]","year":"2013","unstructured":"Teflaro [package insert]. St Louis, MO: Forest Pharmaceuticals, Inc; 2013."},{"issue":"3","key":"i1551-6776-20-6-476-b6","series-title":"Clin Infect Dis","first-page":"e18","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistantStaphylococcus aureus infections in adults and children","volume":"52","year":"2011","unstructured":"Liu\n              C, \n            \n              Bayer\n              A, \n            \n              Cosgrove\n              SE, \n          \n          et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistantStaphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u2013e55."},{"issue":"2","key":"i1551-6776-20-6-476-b7","series-title":"Clin Infect Dis","first-page":"e10","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","year":"2014","unstructured":"Dennis\n              S, \n            \n              Alan\n              B, \n            \n              Henry\n              C, \n          \n          et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10\u2013e52."},{"key":"i1551-6776-20-6-476-b8","series-title":"Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement","year":"2009","unstructured":"Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. CLSI publication M100-S16."},{"issue":"1","key":"i1551-6776-20-6-476-b9","series-title":"Am J Health Syst Pharm","first-page":"82","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Disease Pharmacists","volume":"66","year":"2009","unstructured":"Ryback\n              M, \n            \n              Lomaestro\n              B, \n            \n              Rotschafer\n              JC, \n          \n          et al. Therapeutic monitoring of vancomycin in adult patients: a consensus of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Disease Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398."},{"issue":"suppl 3","key":"i1551-6776-20-6-476-b10","series-title":"Clin Infect Dis","first-page":"S181","article-title":"Activity analyses of Staphylococcal isolates from pedatric, adult, and elderly patients: AWARE ceftaroline surveillance program","volume":"55","year":"2012","unstructured":"Sader\n              HR, \n            \n              Flamm\n              RK, \n            \n              Farrell\n              DJ, \n          \n          et al. Activity analyses of Staphylococcal isolates from pedatric, adult, and elderly patients: AWARE ceftaroline surveillance program. Clin Infect Dis. 2012;55(suppl 3):S181\u2013S186."},{"key":"i1551-6776-20-6-476-b11","series-title":"ClinicalTrials.gov [Internet]","article-title":"Safety and efficacy study of ceftaroline versus a comparator in pediatric patients with complicated community acquired pneumonia (CABP)","unstructured":"Cerexa, Inc.\n          Safety and efficacy study of ceftaroline versus a comparator in pediatric patients with complicated community acquired pneumonia (CABP). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000-[20131010]. http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01669980?term=ceftaroline&rank=6. NLM Identifier: NCT01669980. Accessed October 20, 2015."},{"key":"i1551-6776-20-6-476-b12","series-title":"ClinicalTrials.gov [Internet]","article-title":"Safety and efficacy study of ceftaroline versus a comparator in pediatric subjects with complicated skin infections","unstructured":"Cerexa Inc, AstraZeneca. Safety and efficacy study of ceftaroline versus a comparator in pediatric subjects with complicated skin infections. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000-[20131010]. http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01400867?term=ceftaroline&rank=10. NLM Identifier: NCT01400867. Accessed October 20, 2015."},{"key":"i1551-6776-20-6-476-b13","series-title":"ClinicalTrials.gov [Internet]","article-title":"Safety and efficacy study of ceftaroline versus a comparator in pediatric subjects with community acquired pneumonia (CABP)","unstructured":"Cerexa Inc, AstraZeneca. Safety and efficacy study of ceftaroline versus a comparator in pediatric subjects with community acquired pneumonia (CABP). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000-[20131010]. http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01530763?term=ceftaroline&rank=5. NLM Identifier: NCT01530763. Accessed October 20, 2015."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/20\/6\/article-p476.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/20\/6\/476\/1786510\/1551-6776-20_6_476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/20\/6\/article-p476.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/20\/6\/article-p476.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:37:48Z","timestamp":1747355868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/20\/6\/article-p476.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":13,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-20.6.476","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}